| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 171 | 2024 | 2415 | 15.210 |
Why?
|
| Neoplasms | 195 | 2024 | 3043 | 14.220 |
Why?
|
| Pharmacogenetics | 76 | 2024 | 443 | 9.870 |
Why?
|
| Glucuronosyltransferase | 50 | 2015 | 186 | 6.460 |
Why?
|
| Camptothecin | 53 | 2020 | 196 | 6.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 45 | 2014 | 277 | 4.570 |
Why?
|
| Clinical Trials, Phase II as Topic | 24 | 2022 | 172 | 4.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 69 | 2021 | 2567 | 4.500 |
Why?
|
| Clinical Trials as Topic | 45 | 2024 | 1150 | 4.370 |
Why?
|
| Clinical Trials, Phase I as Topic | 32 | 2022 | 156 | 4.150 |
Why?
|
| Medical Oncology | 18 | 2024 | 384 | 3.980 |
Why?
|
| Research Design | 33 | 2024 | 600 | 3.970 |
Why?
|
| Humans | 548 | 2024 | 89391 | 3.960 |
Why?
|
| Dose-Response Relationship, Drug | 66 | 2023 | 1942 | 3.310 |
Why?
|
| Drug Approval | 7 | 2024 | 66 | 3.220 |
Why?
|
| Maximum Tolerated Dose | 27 | 2023 | 272 | 3.180 |
Why?
|
| Pyridines | 19 | 2022 | 315 | 3.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 18 | 2023 | 969 | 2.910 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 13 | 2022 | 203 | 2.660 |
Why?
|
| Food-Drug Interactions | 8 | 2017 | 19 | 2.660 |
Why?
|
| Lung Neoplasms | 25 | 2023 | 2364 | 2.590 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2023 | 1121 | 2.580 |
Why?
|
| Protein Kinase Inhibitors | 16 | 2022 | 605 | 2.540 |
Why?
|
| Biopsy | 12 | 2024 | 1185 | 2.440 |
Why?
|
| Polymorphism, Genetic | 31 | 2021 | 825 | 2.420 |
Why?
|
| Benzenesulfonates | 12 | 2012 | 66 | 2.370 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2022 | 839 | 2.370 |
Why?
|
| Piperidines | 7 | 2022 | 166 | 2.270 |
Why?
|
| Aged | 207 | 2024 | 19178 | 2.190 |
Why?
|
| Endpoint Determination | 11 | 2024 | 61 | 2.150 |
Why?
|
| United States Food and Drug Administration | 14 | 2024 | 135 | 2.060 |
Why?
|
| Drug Labeling | 9 | 2017 | 41 | 2.050 |
Why?
|
| Drug Administration Schedule | 58 | 2020 | 895 | 2.040 |
Why?
|
| Adenine | 12 | 2022 | 88 | 2.010 |
Why?
|
| Middle Aged | 220 | 2024 | 25995 | 1.980 |
Why?
|
| Genotype | 53 | 2022 | 1849 | 1.940 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 5 | 2018 | 121 | 1.870 |
Why?
|
| Male | 242 | 2024 | 42434 | 1.860 |
Why?
|
| Antimetabolites, Antineoplastic | 14 | 2020 | 244 | 1.860 |
Why?
|
| Polymorphism, Single Nucleotide | 36 | 2024 | 2403 | 1.810 |
Why?
|
| Enzyme Inhibitors | 13 | 2017 | 645 | 1.800 |
Why?
|
| Drugs, Investigational | 11 | 2018 | 39 | 1.790 |
Why?
|
| Economics, Pharmaceutical | 3 | 2023 | 10 | 1.790 |
Why?
|
| Sirolimus | 7 | 2018 | 170 | 1.780 |
Why?
|
| Drug Monitoring | 9 | 2024 | 119 | 1.780 |
Why?
|
| Drug Interactions | 24 | 2022 | 245 | 1.770 |
Why?
|
| Biomarkers, Tumor | 21 | 2024 | 1552 | 1.760 |
Why?
|
| Androstenes | 5 | 2021 | 45 | 1.760 |
Why?
|
| Pharmacogenomic Testing | 16 | 2022 | 98 | 1.740 |
Why?
|
| Female | 247 | 2024 | 46238 | 1.730 |
Why?
|
| Precision Medicine | 19 | 2022 | 412 | 1.720 |
Why?
|
| Fluorouracil | 29 | 2021 | 561 | 1.700 |
Why?
|
| Adult | 190 | 2022 | 26631 | 1.680 |
Why?
|
| Aged, 80 and over | 87 | 2021 | 6817 | 1.670 |
Why?
|
| Neutropenia | 28 | 2019 | 216 | 1.630 |
Why?
|
| Biomedical Research | 6 | 2024 | 398 | 1.610 |
Why?
|
| Deoxycytidine | 11 | 2019 | 238 | 1.590 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2022 | 198 | 1.550 |
Why?
|
| Administration, Oral | 32 | 2024 | 682 | 1.490 |
Why?
|
| Cost-Benefit Analysis | 8 | 2024 | 462 | 1.480 |
Why?
|
| United States | 38 | 2024 | 6999 | 1.450 |
Why?
|
| Paclitaxel | 22 | 2021 | 479 | 1.450 |
Why?
|
| Antibodies, Monoclonal | 11 | 2021 | 1412 | 1.440 |
Why?
|
| Drug Industry | 6 | 2021 | 54 | 1.380 |
Why?
|
| Etoposide | 17 | 2009 | 206 | 1.380 |
Why?
|
| Genome, Human | 10 | 2019 | 767 | 1.360 |
Why?
|
| Pharmacology, Clinical | 4 | 2020 | 8 | 1.340 |
Why?
|
| ErbB Receptors | 8 | 2021 | 501 | 1.320 |
Why?
|
| Treatment Outcome | 59 | 2023 | 8247 | 1.310 |
Why?
|
| Patient Selection | 11 | 2018 | 684 | 1.270 |
Why?
|
| Cytochrome P-450 CYP2D6 | 9 | 2022 | 52 | 1.260 |
Why?
|
| Breast Neoplasms | 25 | 2023 | 3013 | 1.260 |
Why?
|
| Microsomes, Liver | 17 | 2017 | 49 | 1.240 |
Why?
|
| Thrombocytopenia | 18 | 2022 | 187 | 1.230 |
Why?
|
| Colorectal Neoplasms | 17 | 2024 | 983 | 1.220 |
Why?
|
| Suramin | 11 | 2004 | 27 | 1.210 |
Why?
|
| Quinazolines | 10 | 2010 | 221 | 1.210 |
Why?
|
| Sulfonamides | 9 | 2017 | 318 | 1.190 |
Why?
|
| Pyrimidines | 6 | 2021 | 374 | 1.180 |
Why?
|
| Infusions, Intravenous | 38 | 2017 | 435 | 1.170 |
Why?
|
| Melanoma | 6 | 2020 | 468 | 1.170 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2012 | 307 | 1.160 |
Why?
|
| Cisplatin | 20 | 2021 | 618 | 1.130 |
Why?
|
| Phenylurea Compounds | 16 | 2018 | 115 | 1.090 |
Why?
|
| Drug Dosage Calculations | 5 | 2020 | 16 | 1.090 |
Why?
|
| Genome-Wide Association Study | 25 | 2024 | 1674 | 1.080 |
Why?
|
| Angiogenesis Inhibitors | 10 | 2021 | 317 | 1.070 |
Why?
|
| Food | 4 | 2018 | 90 | 1.070 |
Why?
|
| Ketoconazole | 6 | 2017 | 26 | 1.050 |
Why?
|
| Molecular Targeted Therapy | 5 | 2018 | 286 | 1.040 |
Why?
|
| Drug Costs | 3 | 2024 | 63 | 1.030 |
Why?
|
| Drug Prescriptions | 8 | 2022 | 144 | 1.020 |
Why?
|
| Pharmaceutical Preparations | 5 | 2024 | 92 | 0.990 |
Why?
|
| Kidney Neoplasms | 13 | 2014 | 638 | 0.990 |
Why?
|
| Glucuronides | 14 | 2017 | 34 | 0.980 |
Why?
|
| Genetic Variation | 17 | 2020 | 1376 | 0.980 |
Why?
|
| Tamoxifen | 6 | 2018 | 168 | 0.970 |
Why?
|
| Niacinamide | 15 | 2014 | 117 | 0.960 |
Why?
|
| Models, Biological | 26 | 2019 | 1766 | 0.960 |
Why?
|
| Area Under Curve | 28 | 2019 | 337 | 0.960 |
Why?
|
| Genetic Therapy | 2 | 2023 | 370 | 0.950 |
Why?
|
| HIV Protease Inhibitors | 2 | 2022 | 21 | 0.950 |
Why?
|
| Isoenzymes | 9 | 2015 | 274 | 0.940 |
Why?
|
| Anemia | 6 | 2022 | 130 | 0.940 |
Why?
|
| Imides | 9 | 2001 | 26 | 0.940 |
Why?
|
| Phosphotransferases | 2 | 2017 | 65 | 0.930 |
Why?
|
| Prospective Studies | 27 | 2022 | 4293 | 0.930 |
Why?
|
| Orphan Drug Production | 1 | 2023 | 4 | 0.910 |
Why?
|
| Isoquinolines | 9 | 2001 | 72 | 0.910 |
Why?
|
| Carcinoma, Renal Cell | 11 | 2014 | 437 | 0.910 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 3 | 2022 | 12 | 0.890 |
Why?
|
| Carbolines | 3 | 2022 | 8 | 0.890 |
Why?
|
| Decision Support Systems, Clinical | 5 | 2019 | 104 | 0.890 |
Why?
|
| Liver | 18 | 2020 | 1208 | 0.890 |
Why?
|
| Leukemia, Hairy Cell | 26 | 1994 | 186 | 0.890 |
Why?
|
| Conflict of Interest | 5 | 2015 | 68 | 0.890 |
Why?
|
| Indoles | 6 | 2017 | 314 | 0.880 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2015 | 175 | 0.880 |
Why?
|
| Body Surface Area | 6 | 2022 | 36 | 0.870 |
Why?
|
| Ethics Committees, Research | 2 | 2022 | 33 | 0.860 |
Why?
|
| Leukemia | 9 | 2021 | 323 | 0.840 |
Why?
|
| Prodrugs | 5 | 2008 | 50 | 0.840 |
Why?
|
| Quinoxalines | 4 | 2014 | 50 | 0.830 |
Why?
|
| Piperazines | 3 | 2022 | 283 | 0.820 |
Why?
|
| Ritonavir | 1 | 2022 | 12 | 0.820 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2021 | 12 | 0.800 |
Why?
|
| Bevacizumab | 13 | 2024 | 289 | 0.800 |
Why?
|
| Physicians | 3 | 2021 | 690 | 0.800 |
Why?
|
| Leucovorin | 18 | 2021 | 224 | 0.800 |
Why?
|
| Fear | 1 | 2022 | 79 | 0.790 |
Why?
|
| Liver Diseases | 4 | 2007 | 242 | 0.790 |
Why?
|
| Diarrhea | 10 | 2009 | 182 | 0.790 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2012 | 116 | 0.790 |
Why?
|
| Prostatic Neoplasms | 13 | 2024 | 1769 | 0.790 |
Why?
|
| Computer Simulation | 6 | 2023 | 1098 | 0.790 |
Why?
|
| Patents as Topic | 1 | 2021 | 12 | 0.780 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 60 | 0.780 |
Why?
|
| Patient Harm | 1 | 2021 | 7 | 0.780 |
Why?
|
| Antifungal Agents | 3 | 2007 | 120 | 0.770 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2020 | 91 | 0.770 |
Why?
|
| Industry | 3 | 2023 | 17 | 0.770 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 144 | 0.770 |
Why?
|
| Health Care Costs | 3 | 2021 | 235 | 0.770 |
Why?
|
| Topotecan | 9 | 2005 | 45 | 0.750 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 10 | 0.750 |
Why?
|
| Biological Products | 2 | 2020 | 155 | 0.750 |
Why?
|
| Metabolic Clearance Rate | 17 | 2017 | 120 | 0.740 |
Why?
|
| Methyltransferases | 5 | 2013 | 192 | 0.740 |
Why?
|
| Informed Consent | 11 | 2022 | 275 | 0.730 |
Why?
|
| Taxoids | 6 | 2016 | 130 | 0.720 |
Why?
|
| Multidrug Resistance-Associated Proteins | 5 | 2013 | 27 | 0.710 |
Why?
|
| Pharmacogenomic Variants | 4 | 2021 | 42 | 0.700 |
Why?
|
| Creatinine | 6 | 2015 | 293 | 0.690 |
Why?
|
| Cytochrome P-450 CYP3A | 10 | 2017 | 42 | 0.680 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2019 | 13 | 0.660 |
Why?
|
| Research | 4 | 2019 | 252 | 0.660 |
Why?
|
| Triazoles | 4 | 2012 | 102 | 0.650 |
Why?
|
| Interleukin-6 | 1 | 2020 | 261 | 0.650 |
Why?
|
| Topoisomerase II Inhibitors | 4 | 2009 | 27 | 0.650 |
Why?
|
| Kidney Diseases | 4 | 2007 | 319 | 0.650 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 173 | 0.640 |
Why?
|
| Doxorubicin | 9 | 2007 | 301 | 0.640 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2018 | 188 | 0.640 |
Why?
|
| Interferon-alpha | 16 | 2004 | 226 | 0.630 |
Why?
|
| Caffeine | 1 | 2019 | 83 | 0.620 |
Why?
|
| Physician's Role | 2 | 2017 | 177 | 0.610 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 147 | 0.610 |
Why?
|
| National Cancer Institute (U.S.) | 7 | 2023 | 73 | 0.610 |
Why?
|
| Megestrol Acetate | 1 | 2017 | 10 | 0.600 |
Why?
|
| Metabolome | 2 | 2017 | 49 | 0.600 |
Why?
|
| Pyrazoles | 5 | 2022 | 150 | 0.600 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 361 | 0.590 |
Why?
|
| Protein Kinases | 3 | 2009 | 213 | 0.590 |
Why?
|
| Hydroxamic Acids | 3 | 2014 | 51 | 0.590 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2021 | 602 | 0.580 |
Why?
|
| Parkinson Disease | 1 | 2019 | 146 | 0.580 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 28 | 0.580 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 10 | 2006 | 29 | 0.570 |
Why?
|
| Nontherapeutic Human Experimentation | 7 | 2017 | 20 | 0.570 |
Why?
|
| Neovascularization, Pathologic | 5 | 2018 | 364 | 0.560 |
Why?
|
| Carboplatin | 5 | 2021 | 312 | 0.560 |
Why?
|
| Immunotherapy | 2 | 2020 | 687 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 1048 | 0.560 |
Why?
|
| Perioperative Care | 5 | 2022 | 169 | 0.550 |
Why?
|
| Guanine | 4 | 2002 | 207 | 0.540 |
Why?
|
| Recombinant Proteins | 30 | 2017 | 1012 | 0.540 |
Why?
|
| Kidney | 6 | 2015 | 1147 | 0.540 |
Why?
|
| Leukopenia | 12 | 2002 | 66 | 0.530 |
Why?
|
| Germ-Line Mutation | 7 | 2020 | 347 | 0.520 |
Why?
|
| Capecitabine | 6 | 2020 | 98 | 0.520 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 160 | 0.510 |
Why?
|
| Topoisomerase I Inhibitors | 7 | 2020 | 34 | 0.510 |
Why?
|
| Attitude of Health Personnel | 4 | 2019 | 651 | 0.510 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2020 | 618 | 0.510 |
Why?
|
| Pancreatic Neoplasms | 4 | 2019 | 674 | 0.510 |
Why?
|
| RNA, Messenger | 14 | 2018 | 2017 | 0.510 |
Why?
|
| Oxidoreductases | 10 | 2002 | 112 | 0.500 |
Why?
|
| Uracil | 7 | 2002 | 55 | 0.500 |
Why?
|
| Introns | 4 | 2013 | 299 | 0.500 |
Why?
|
| Depsipeptides | 1 | 2015 | 30 | 0.500 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2013 | 44 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2019 | 2343 | 0.500 |
Why?
|
| Prostate-Specific Antigen | 5 | 2018 | 360 | 0.500 |
Why?
|
| Meaningful Use | 1 | 2014 | 2 | 0.500 |
Why?
|
| Morpholines | 1 | 2015 | 69 | 0.500 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2005 | 68 | 0.490 |
Why?
|
| Carbazoles | 2 | 2005 | 33 | 0.490 |
Why?
|
| Head and Neck Neoplasms | 10 | 2008 | 1063 | 0.490 |
Why?
|
| Professional Practice | 1 | 2015 | 46 | 0.480 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 98 | 0.480 |
Why?
|
| Lymphoma | 7 | 2021 | 265 | 0.470 |
Why?
|
| Time Factors | 22 | 2020 | 5340 | 0.470 |
Why?
|
| Hypertension, Pulmonary | 3 | 2022 | 353 | 0.470 |
Why?
|
| Cohort Studies | 18 | 2019 | 2873 | 0.470 |
Why?
|
| Bilirubin | 13 | 2010 | 131 | 0.470 |
Why?
|
| Reproducibility of Results | 11 | 2021 | 2759 | 0.460 |
Why?
|
| Regression Analysis | 14 | 2010 | 590 | 0.460 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 1198 | 0.460 |
Why?
|
| Sample Size | 3 | 2011 | 128 | 0.460 |
Why?
|
| Hypertension | 3 | 2021 | 746 | 0.450 |
Why?
|
| Interferon Type I | 17 | 1990 | 185 | 0.450 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 67 | 0.450 |
Why?
|
| Linkage Disequilibrium | 7 | 2013 | 477 | 0.450 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 48 | 0.450 |
Why?
|
| Young Adult | 22 | 2020 | 6317 | 0.440 |
Why?
|
| Program Development | 1 | 2014 | 123 | 0.440 |
Why?
|
| Biological Availability | 7 | 2017 | 92 | 0.440 |
Why?
|
| Dietary Fats | 1 | 2014 | 135 | 0.440 |
Why?
|
| Risk Assessment | 19 | 2021 | 2305 | 0.440 |
Why?
|
| Drug Delivery Systems | 2 | 2012 | 179 | 0.440 |
Why?
|
| Hearing Loss | 1 | 2013 | 59 | 0.430 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 69 | 0.430 |
Why?
|
| Ambulatory Care | 2 | 2014 | 187 | 0.430 |
Why?
|
| Models, Statistical | 8 | 2020 | 576 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2004 | 49 | 0.430 |
Why?
|
| Food Labeling | 1 | 2012 | 8 | 0.430 |
Why?
|
| Drug Therapy | 5 | 2016 | 70 | 0.430 |
Why?
|
| Indazoles | 5 | 2017 | 67 | 0.430 |
Why?
|
| Cladribine | 5 | 2004 | 35 | 0.420 |
Why?
|
| Phenotype | 19 | 2020 | 2443 | 0.420 |
Why?
|
| Enzymes | 2 | 2006 | 47 | 0.420 |
Why?
|
| Equivalence Trials as Topic | 2 | 2024 | 6 | 0.420 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 219 | 0.420 |
Why?
|
| Universities | 1 | 2013 | 148 | 0.420 |
Why?
|
| Private Sector | 2 | 2011 | 19 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2018 | 424 | 0.420 |
Why?
|
| Glucuronates | 8 | 2007 | 22 | 0.400 |
Why?
|
| Snake Venoms | 2 | 2015 | 10 | 0.400 |
Why?
|
| Medicine | 3 | 2007 | 91 | 0.400 |
Why?
|
| Clinical Protocols | 2 | 2014 | 157 | 0.400 |
Why?
|
| Investments | 1 | 2011 | 6 | 0.400 |
Why?
|
| Pyrazolones | 2 | 2002 | 4 | 0.390 |
Why?
|
| Warfarin | 3 | 2019 | 104 | 0.390 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2018 | 157 | 0.390 |
Why?
|
| Patient Safety | 2 | 2020 | 217 | 0.390 |
Why?
|
| Haplotypes | 7 | 2012 | 637 | 0.390 |
Why?
|
| Mass Media | 1 | 2011 | 26 | 0.390 |
Why?
|
| Commerce | 1 | 2011 | 31 | 0.390 |
Why?
|
| Vinblastine | 7 | 1998 | 108 | 0.390 |
Why?
|
| Technology, Pharmaceutical | 2 | 2009 | 33 | 0.380 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 385 | 0.380 |
Why?
|
| Neoplasm Staging | 14 | 2021 | 2018 | 0.380 |
Why?
|
| Germ Cells | 1 | 2012 | 130 | 0.380 |
Why?
|
| Cost Sharing | 1 | 2011 | 17 | 0.380 |
Why?
|
| Kinetics | 10 | 2017 | 1528 | 0.370 |
Why?
|
| Interleukin-17 | 1 | 2011 | 105 | 0.370 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 1976 | 0.370 |
Why?
|
| Body Weight | 4 | 2020 | 452 | 0.370 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 60 | 0.370 |
Why?
|
| Eating | 2 | 2012 | 166 | 0.370 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 282 | 0.370 |
Why?
|
| Cyclosporine | 5 | 2007 | 237 | 0.360 |
Why?
|
| Mutation | 8 | 2021 | 4143 | 0.360 |
Why?
|
| Health Resources | 1 | 2011 | 81 | 0.360 |
Why?
|
| Research Subjects | 9 | 2007 | 73 | 0.360 |
Why?
|
| Alleles | 6 | 2017 | 1136 | 0.360 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 3667 | 0.350 |
Why?
|
| Patient Portals | 2 | 2020 | 18 | 0.350 |
Why?
|
| Aminopyridines | 2 | 2022 | 40 | 0.350 |
Why?
|
| Cost Savings | 2 | 2020 | 69 | 0.340 |
Why?
|
| Ovarian Neoplasms | 3 | 2008 | 765 | 0.340 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 29 | 0.340 |
Why?
|
| Drug Evaluation | 17 | 2002 | 138 | 0.340 |
Why?
|
| Population Groups | 1 | 2009 | 41 | 0.340 |
Why?
|
| Dinucleotide Repeats | 1 | 2009 | 14 | 0.330 |
Why?
|
| Hepatic Insufficiency | 1 | 2009 | 1 | 0.330 |
Why?
|
| Drug Design | 8 | 2011 | 127 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 7 | 2012 | 956 | 0.330 |
Why?
|
| Acetylation | 6 | 2021 | 132 | 0.330 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 167 | 0.330 |
Why?
|
| Substrate Specificity | 5 | 2017 | 352 | 0.330 |
Why?
|
| Fatigue | 8 | 2022 | 179 | 0.330 |
Why?
|
| Genetics, Population | 2 | 2009 | 407 | 0.320 |
Why?
|
| Double-Blind Method | 9 | 2019 | 1719 | 0.320 |
Why?
|
| Cell Line, Tumor | 9 | 2018 | 2558 | 0.320 |
Why?
|
| Prescription Drugs | 2 | 2019 | 36 | 0.320 |
Why?
|
| Drug Discovery | 1 | 2009 | 107 | 0.320 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 28 | 0.320 |
Why?
|
| Organizations, Nonprofit | 1 | 2008 | 8 | 0.320 |
Why?
|
| Immunosuppressive Agents | 4 | 2007 | 975 | 0.320 |
Why?
|
| Anesthesiology | 2 | 2022 | 157 | 0.310 |
Why?
|
| Biomedical Technology | 1 | 2008 | 21 | 0.310 |
Why?
|
| Biomarkers | 2 | 2014 | 1767 | 0.310 |
Why?
|
| Organoplatinum Compounds | 4 | 2020 | 97 | 0.310 |
Why?
|
| Disease Progression | 6 | 2012 | 1489 | 0.310 |
Why?
|
| Cytochrome P-450 Enzyme System | 7 | 2008 | 79 | 0.310 |
Why?
|
| Quantitative Trait Loci | 6 | 2024 | 608 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 5 | 2016 | 300 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2014 | 359 | 0.300 |
Why?
|
| Drug Packaging | 3 | 2020 | 7 | 0.300 |
Why?
|
| Salvage Therapy | 4 | 2008 | 236 | 0.290 |
Why?
|
| Government Regulation | 2 | 2007 | 49 | 0.290 |
Why?
|
| Genetic Privacy | 1 | 2007 | 12 | 0.290 |
Why?
|
| Tubulin Modulators | 2 | 2020 | 24 | 0.290 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 433 | 0.290 |
Why?
|
| Liposomes | 2 | 2004 | 93 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 275 | 0.290 |
Why?
|
| Decision Making | 5 | 2018 | 667 | 0.290 |
Why?
|
| DNA-Binding Proteins | 4 | 2012 | 1242 | 0.280 |
Why?
|
| Models, Genetic | 1 | 2012 | 946 | 0.280 |
Why?
|
| Phenobarbital | 4 | 2006 | 33 | 0.280 |
Why?
|
| Prejudice | 1 | 2007 | 48 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 538 | 0.280 |
Why?
|
| Medical Records | 2 | 2007 | 120 | 0.280 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2014 | 92 | 0.280 |
Why?
|
| Intestinal Absorption | 3 | 2017 | 124 | 0.280 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 435 | 0.270 |
Why?
|
| Naphthalimides | 9 | 2001 | 17 | 0.270 |
Why?
|
| Technology Transfer | 1 | 2006 | 3 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 260 | 0.270 |
Why?
|
| Disease-Free Survival | 8 | 2016 | 1214 | 0.270 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 784 | 0.270 |
Why?
|
| Radiosurgery | 2 | 2021 | 288 | 0.270 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 2 | 2017 | 5 | 0.270 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2010 | 90 | 0.270 |
Why?
|
| Organophosphonates | 9 | 2001 | 50 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 85 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2013 | 394 | 0.260 |
Why?
|
| Abiraterone Acetate | 2 | 2018 | 12 | 0.260 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2005 | 41 | 0.260 |
Why?
|
| Prognosis | 14 | 2021 | 3787 | 0.260 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2002 | 118 | 0.260 |
Why?
|
| Pharmacy and Therapeutics Committee | 3 | 2010 | 5 | 0.250 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2019 | 20 | 0.250 |
Why?
|
| Survival Analysis | 12 | 2018 | 1534 | 0.250 |
Why?
|
| Receptor, trkA | 1 | 2005 | 15 | 0.250 |
Why?
|
| Liver Neoplasms | 3 | 2013 | 759 | 0.250 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2010 | 162 | 0.240 |
Why?
|
| Anthraquinones | 2 | 2002 | 8 | 0.240 |
Why?
|
| Dipeptides | 1 | 2004 | 42 | 0.240 |
Why?
|
| Chicago | 4 | 2014 | 1427 | 0.240 |
Why?
|
| Maytansine | 1 | 2004 | 10 | 0.240 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 122 | 0.240 |
Why?
|
| Thionucleotides | 2 | 2002 | 56 | 0.240 |
Why?
|
| Genomics | 3 | 2019 | 763 | 0.240 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2024 | 17 | 0.240 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2004 | 112 | 0.240 |
Why?
|
| Clinical Medicine | 3 | 2015 | 34 | 0.240 |
Why?
|
| Fasting | 2 | 2018 | 163 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2005 | 231 | 0.230 |
Why?
|
| Information Dissemination | 3 | 2019 | 115 | 0.230 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2010 | 217 | 0.230 |
Why?
|
| Risk Factors | 12 | 2024 | 5497 | 0.230 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2003 | 166 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2018 | 1365 | 0.230 |
Why?
|
| Acetyltransferases | 2 | 2021 | 33 | 0.230 |
Why?
|
| Glutathione Transferase | 6 | 2005 | 112 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2023 | 38 | 0.230 |
Why?
|
| Greenhouse Gases | 1 | 2023 | 1 | 0.230 |
Why?
|
| Animals | 25 | 2016 | 27387 | 0.230 |
Why?
|
| Genetic Markers | 3 | 2018 | 478 | 0.220 |
Why?
|
| Interleukin-2 | 7 | 2004 | 251 | 0.220 |
Why?
|
| Pyrazines | 4 | 2000 | 94 | 0.220 |
Why?
|
| Physician-Patient Relations | 4 | 2019 | 625 | 0.220 |
Why?
|
| Government | 1 | 2023 | 9 | 0.220 |
Why?
|
| Neoplasm Metastasis | 11 | 2024 | 1110 | 0.220 |
Why?
|
| Fever | 3 | 2020 | 128 | 0.210 |
Why?
|
| Sensory Receptor Cells | 2 | 2014 | 37 | 0.210 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2008 | 20 | 0.210 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 117 | 0.210 |
Why?
|
| Prednisone | 4 | 2018 | 259 | 0.210 |
Why?
|
| Dioxolanes | 1 | 2002 | 8 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2010 | 261 | 0.210 |
Why?
|
| Apoptosis | 2 | 2008 | 1717 | 0.210 |
Why?
|
| Survival Rate | 10 | 2021 | 1903 | 0.210 |
Why?
|
| DNA Damage | 2 | 2017 | 371 | 0.210 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2004 | 61 | 0.210 |
Why?
|
| Alanine | 2 | 2019 | 83 | 0.210 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2013 | 82 | 0.210 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2016 | 142 | 0.210 |
Why?
|
| Lactams | 1 | 2022 | 11 | 0.210 |
Why?
|
| DNA, Antisense | 1 | 2002 | 15 | 0.210 |
Why?
|
| Lactams, Macrocyclic | 1 | 2022 | 14 | 0.210 |
Why?
|
| Transcription, Genetic | 3 | 2017 | 1157 | 0.200 |
Why?
|
| Triazines | 2 | 2019 | 53 | 0.200 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.200 |
Why?
|
| Anilides | 2 | 2013 | 48 | 0.200 |
Why?
|
| Reimbursement, Incentive | 1 | 2022 | 37 | 0.200 |
Why?
|
| Leukemia, Myeloid | 2 | 2014 | 249 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 428 | 0.200 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2021 | 14 | 0.200 |
Why?
|
| Celecoxib | 2 | 2019 | 31 | 0.200 |
Why?
|
| Genetic Testing | 4 | 2019 | 538 | 0.200 |
Why?
|
| Pain Management | 2 | 2021 | 138 | 0.200 |
Why?
|
| Uridine Diphosphate | 2 | 1998 | 5 | 0.200 |
Why?
|
| Stomatitis | 5 | 2004 | 30 | 0.190 |
Why?
|
| Biotransformation | 6 | 2009 | 50 | 0.190 |
Why?
|
| Cytosine | 1 | 2002 | 128 | 0.190 |
Why?
|
| Proteinuria | 1 | 2021 | 67 | 0.190 |
Why?
|
| Mercaptopurine | 3 | 2009 | 53 | 0.190 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 16 | 0.190 |
Why?
|
| Oxidation-Reduction | 3 | 2017 | 388 | 0.190 |
Why?
|
| Aminoquinolines | 1 | 2001 | 17 | 0.190 |
Why?
|
| Indenes | 1 | 2001 | 10 | 0.190 |
Why?
|
| Intercalating Agents | 2 | 1993 | 12 | 0.190 |
Why?
|
| Epothilones | 2 | 2019 | 13 | 0.190 |
Why?
|
| Acrylamides | 1 | 2021 | 34 | 0.190 |
Why?
|
| Human Genome Project | 1 | 2001 | 19 | 0.190 |
Why?
|
| Nitriles | 2 | 2012 | 160 | 0.190 |
Why?
|
| Hockey | 1 | 2021 | 9 | 0.190 |
Why?
|
| Protein Kinase C | 1 | 2002 | 268 | 0.190 |
Why?
|
| Anesthetics | 1 | 2021 | 52 | 0.190 |
Why?
|
| Research Personnel | 2 | 2001 | 71 | 0.190 |
Why?
|
| Patient Participation | 4 | 2015 | 225 | 0.190 |
Why?
|
| Government Agencies | 1 | 2020 | 11 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 207 | 0.190 |
Why?
|
| Hematologic Neoplasms | 3 | 2014 | 343 | 0.180 |
Why?
|
| Collagen | 1 | 2002 | 293 | 0.180 |
Why?
|
| Anticarcinogenic Agents | 3 | 2013 | 73 | 0.180 |
Why?
|
| Antidotes | 2 | 1997 | 23 | 0.180 |
Why?
|
| Bile | 2 | 2002 | 57 | 0.180 |
Why?
|
| Organizational Policy | 1 | 2001 | 55 | 0.180 |
Why?
|
| Sarcoma | 4 | 2009 | 220 | 0.180 |
Why?
|
| Rheumatology | 1 | 2021 | 35 | 0.180 |
Why?
|
| Albumins | 2 | 2019 | 129 | 0.180 |
Why?
|
| Safety | 4 | 2010 | 149 | 0.180 |
Why?
|
| Signal Transduction | 6 | 2013 | 3387 | 0.180 |
Why?
|
| Genotyping Techniques | 3 | 2018 | 69 | 0.180 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 173 | 0.180 |
Why?
|
| Thymidylate Synthase | 4 | 2003 | 13 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 448 | 0.180 |
Why?
|
| Nausea | 5 | 2022 | 176 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2002 | 463 | 0.180 |
Why?
|
| Analgesics | 1 | 2021 | 119 | 0.180 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 113 | 0.180 |
Why?
|
| Splenectomy | 9 | 1992 | 82 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2019 | 578 | 0.180 |
Why?
|
| Remission Induction | 17 | 2008 | 740 | 0.180 |
Why?
|
| Models, Theoretical | 6 | 2014 | 491 | 0.180 |
Why?
|
| Algorithms | 3 | 2019 | 1877 | 0.180 |
Why?
|
| Anesthesia | 1 | 2022 | 165 | 0.170 |
Why?
|
| DNA, Neoplasm | 3 | 2018 | 268 | 0.170 |
Why?
|
| Europe | 1 | 2020 | 322 | 0.170 |
Why?
|
| Schools, Medical | 1 | 2001 | 134 | 0.170 |
Why?
|
| Bone Marrow | 12 | 2001 | 445 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 192 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2018 | 207 | 0.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2017 | 122 | 0.170 |
Why?
|
| Drug Utilization | 1 | 2020 | 66 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 2 | 1992 | 260 | 0.170 |
Why?
|
| Blood Pressure | 3 | 2014 | 900 | 0.170 |
Why?
|
| Circadian Rhythm | 2 | 2015 | 305 | 0.170 |
Why?
|
| Inpatients | 1 | 2022 | 310 | 0.170 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2018 | 58 | 0.170 |
Why?
|
| Leukocyte Count | 10 | 1996 | 223 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 487 | 0.170 |
Why?
|
| Hepatocytes | 4 | 2013 | 119 | 0.170 |
Why?
|
| Cytidine Deaminase | 1 | 2019 | 43 | 0.170 |
Why?
|
| Ethics, Medical | 4 | 2008 | 307 | 0.160 |
Why?
|
| Tegafur | 2 | 1999 | 17 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 147 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1996 | 111 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2008 | 794 | 0.160 |
Why?
|
| Benzamides | 2 | 2013 | 238 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 117 | 0.160 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2018 | 2 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 286 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2005 | 395 | 0.160 |
Why?
|
| Exanthema | 2 | 2009 | 39 | 0.160 |
Why?
|
| Receptors, IgG | 1 | 2018 | 53 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 140 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2020 | 371 | 0.160 |
Why?
|
| Singapore | 1 | 2018 | 16 | 0.160 |
Why?
|
| Cetuximab | 4 | 2021 | 117 | 0.160 |
Why?
|
| Receptors, Estrogen | 3 | 2016 | 393 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 267 | 0.150 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 49 | 0.150 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 47 | 0.150 |
Why?
|
| Troleandomycin | 1 | 2017 | 3 | 0.150 |
Why?
|
| Bone Marrow Diseases | 3 | 1993 | 40 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 131 | 0.150 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2017 | 12 | 0.150 |
Why?
|
| Career Choice | 1 | 2019 | 148 | 0.150 |
Why?
|
| Liver Function Tests | 4 | 2007 | 92 | 0.150 |
Why?
|
| Erythropoietin | 3 | 2013 | 90 | 0.150 |
Why?
|
| Statistics as Topic | 3 | 1993 | 234 | 0.150 |
Why?
|
| Receptors, Calcitriol | 1 | 2018 | 130 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2011 | 312 | 0.140 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 72 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2019 | 221 | 0.140 |
Why?
|
| Diphtheria Toxin | 4 | 1998 | 20 | 0.140 |
Why?
|
| Combined Modality Therapy | 11 | 2021 | 1720 | 0.140 |
Why?
|
| Surveys and Questionnaires | 9 | 2020 | 2633 | 0.140 |
Why?
|
| Adrenal Cortex Diseases | 1 | 1996 | 6 | 0.140 |
Why?
|
| Addison Disease | 1 | 1996 | 4 | 0.140 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2018 | 46 | 0.140 |
Why?
|
| Specialization | 2 | 2007 | 66 | 0.140 |
Why?
|
| Motor Neuron Disease | 1 | 1997 | 21 | 0.140 |
Why?
|
| Valproic Acid | 1 | 1997 | 24 | 0.140 |
Why?
|
| Therapeutic Human Experimentation | 2 | 1993 | 20 | 0.140 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 54 | 0.140 |
Why?
|
| Neural Conduction | 1 | 1997 | 71 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2014 | 8 | 0.140 |
Why?
|
| Demyelinating Diseases | 1 | 1997 | 67 | 0.140 |
Why?
|
| Intersectoral Collaboration | 1 | 2016 | 10 | 0.140 |
Why?
|
| Glioma | 1 | 1999 | 294 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 168 | 0.140 |
Why?
|
| Metformin | 1 | 2018 | 124 | 0.140 |
Why?
|
| Biliary Tract | 1 | 1996 | 12 | 0.140 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 146 | 0.140 |
Why?
|
| Testosterone | 1 | 2018 | 276 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2010 | 1266 | 0.130 |
Why?
|
| Neoplasm Proteins | 5 | 2016 | 540 | 0.130 |
Why?
|
| Critical Care | 1 | 2019 | 380 | 0.130 |
Why?
|
| Cyclophosphamide | 7 | 2002 | 302 | 0.130 |
Why?
|
| Atazanavir Sulfate | 1 | 2015 | 1 | 0.130 |
Why?
|
| Hyperbilirubinemia | 1 | 2015 | 21 | 0.130 |
Why?
|
| Floxuridine | 2 | 1993 | 12 | 0.130 |
Why?
|
| Jaundice | 1 | 2015 | 14 | 0.130 |
Why?
|
| Polyneuropathies | 1 | 2016 | 27 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2004 | 315 | 0.130 |
Why?
|
| Hydroxyurea | 6 | 1998 | 239 | 0.130 |
Why?
|
| Drug Eruptions | 2 | 2006 | 34 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2018 | 358 | 0.130 |
Why?
|
| Flavonoids | 4 | 2007 | 87 | 0.130 |
Why?
|
| Attitude to Health | 4 | 2017 | 222 | 0.130 |
Why?
|
| Random Allocation | 6 | 2008 | 327 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
| Placebos | 3 | 2017 | 214 | 0.130 |
Why?
|
| Selection Bias | 2 | 2011 | 37 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2015 | 89 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 463 | 0.130 |
Why?
|
| Sulfonic Acids | 1 | 1995 | 9 | 0.120 |
Why?
|
| Collagen Type I | 1 | 2015 | 72 | 0.120 |
Why?
|
| Naphthyridines | 1 | 2015 | 27 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2011 | 285 | 0.120 |
Why?
|
| Hydrocortisone | 1 | 1996 | 302 | 0.120 |
Why?
|
| Nitrosamines | 1 | 2014 | 8 | 0.120 |
Why?
|
| Gene Expression Profiling | 6 | 2013 | 1432 | 0.120 |
Why?
|
| Nedocromil | 1 | 2014 | 6 | 0.120 |
Why?
|
| Inactivation, Metabolic | 2 | 2006 | 8 | 0.120 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 86 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 1997 | 326 | 0.120 |
Why?
|
| DNA Primers | 2 | 2006 | 543 | 0.120 |
Why?
|
| Drug Resistance | 3 | 1993 | 232 | 0.120 |
Why?
|
| Comprehension | 5 | 2000 | 82 | 0.120 |
Why?
|
| Lymphopenia | 2 | 2012 | 31 | 0.120 |
Why?
|
| Busulfan | 1 | 2014 | 41 | 0.120 |
Why?
|
| Fees and Charges | 1 | 2014 | 14 | 0.120 |
Why?
|
| Drug Synergism | 5 | 2018 | 306 | 0.120 |
Why?
|
| Adolescent | 11 | 2020 | 9268 | 0.120 |
Why?
|
| Epirubicin | 3 | 2021 | 14 | 0.120 |
Why?
|
| Phthalazines | 1 | 2014 | 45 | 0.120 |
Why?
|
| Aldehyde Oxidase | 1 | 2014 | 3 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 125 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 75 | 0.120 |
Why?
|
| Pyrroles | 2 | 2015 | 187 | 0.120 |
Why?
|
| Azacitidine | 1 | 2014 | 147 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2013 | 3 | 0.110 |
Why?
|
| Receptors, Interleukin-2 | 5 | 1998 | 67 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2014 | 120 | 0.110 |
Why?
|
| Sex Factors | 5 | 2020 | 1068 | 0.110 |
Why?
|
| Disclosure | 5 | 2000 | 110 | 0.110 |
Why?
|
| Organic Cation Transporter 1 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2014 | 75 | 0.110 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2013 | 30 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 84 | 0.110 |
Why?
|
| Portraits as Topic | 1 | 2013 | 6 | 0.110 |
Why?
|
| Child | 9 | 2020 | 7175 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1999 | 1097 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 3 | 1997 | 133 | 0.110 |
Why?
|
| Arteries | 1 | 2014 | 180 | 0.110 |
Why?
|
| Medicare | 1 | 2017 | 425 | 0.110 |
Why?
|
| Brain Diseases | 1 | 1995 | 186 | 0.110 |
Why?
|
| Erythropoiesis | 1 | 2013 | 51 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 950 | 0.110 |
Why?
|
| Imatinib Mesylate | 1 | 2013 | 127 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 782 | 0.110 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2013 | 5 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 1243 | 0.110 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 34 | 0.110 |
Why?
|
| Transfection | 4 | 2011 | 911 | 0.110 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 1992 | 3 | 0.110 |
Why?
|
| Axons | 1 | 2014 | 181 | 0.110 |
Why?
|
| Health Policy | 1 | 2015 | 185 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 1995 | 314 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2012 | 16 | 0.110 |
Why?
|
| Nicotine | 1 | 2014 | 199 | 0.110 |
Why?
|
| Leukemia, B-Cell | 1 | 1992 | 23 | 0.110 |
Why?
|
| Trastuzumab | 2 | 2023 | 74 | 0.110 |
Why?
|
| Citrus paradisi | 1 | 2012 | 5 | 0.110 |
Why?
|
| Conserved Sequence | 1 | 2013 | 211 | 0.110 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2009 | 21 | 0.110 |
Why?
|
| Binding, Competitive | 2 | 2010 | 146 | 0.100 |
Why?
|
| Skin Neoplasms | 5 | 2020 | 581 | 0.100 |
Why?
|
| Androstenols | 1 | 2012 | 3 | 0.100 |
Why?
|
| Quality of Life | 5 | 2020 | 1669 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 860 | 0.100 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 14 | 0.100 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 170 | 0.100 |
Why?
|
| Orchiectomy | 1 | 2012 | 72 | 0.100 |
Why?
|
| Cells, Cultured | 3 | 2020 | 2884 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2017 | 125 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 159 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2013 | 208 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 92 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2009 | 128 | 0.100 |
Why?
|
| Logistic Models | 4 | 1999 | 1213 | 0.100 |
Why?
|
| Hydroxylation | 2 | 2009 | 17 | 0.100 |
Why?
|
| Postmenopause | 1 | 2012 | 102 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2018 | 1132 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 648 | 0.100 |
Why?
|
| Therapeutic Equivalency | 2 | 2021 | 15 | 0.100 |
Why?
|
| Students | 1 | 2013 | 170 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2019 | 427 | 0.100 |
Why?
|
| Hemoglobins | 2 | 1991 | 192 | 0.100 |
Why?
|
| Pentostatin | 7 | 2002 | 30 | 0.100 |
Why?
|
| Rats | 5 | 2013 | 4041 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 23 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 695 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2014 | 755 | 0.100 |
Why?
|
| Patient Care | 1 | 2012 | 102 | 0.100 |
Why?
|
| Thalidomide | 1 | 2011 | 57 | 0.100 |
Why?
|
| Adenoma | 1 | 2013 | 247 | 0.100 |
Why?
|
| Androstadienes | 1 | 2011 | 72 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 887 | 0.100 |
Why?
|
| Cyclosporins | 1 | 1991 | 58 | 0.090 |
Why?
|
| Verapamil | 1 | 1991 | 34 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2012 | 172 | 0.090 |
Why?
|
| Multivariate Analysis | 5 | 2009 | 988 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2002 | 1057 | 0.090 |
Why?
|
| Maryland | 1 | 2011 | 42 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2011 | 89 | 0.090 |
Why?
|
| Pharmacoepidemiology | 1 | 2010 | 6 | 0.090 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2011 | 48 | 0.090 |
Why?
|
| Acetaminophen | 1 | 2011 | 56 | 0.090 |
Why?
|
| Gene Frequency | 4 | 2008 | 685 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1725 | 0.090 |
Why?
|
| DNA Repair | 2 | 2003 | 362 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 338 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2012 | 162 | 0.090 |
Why?
|
| Thyroxine | 2 | 2015 | 353 | 0.090 |
Why?
|
| Cholestasis | 1 | 1990 | 45 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2009 | 80 | 0.090 |
Why?
|
| Feasibility Studies | 5 | 2004 | 782 | 0.090 |
Why?
|
| Microtubules | 2 | 2004 | 123 | 0.090 |
Why?
|
| Efficiency | 1 | 2010 | 40 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 713 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 420 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 622 | 0.090 |
Why?
|
| Glycosylation | 1 | 2010 | 128 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 32 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 77 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2013 | 146 | 0.090 |
Why?
|
| Indinavir | 2 | 2010 | 3 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1840 | 0.090 |
Why?
|
| Half-Life | 5 | 2008 | 97 | 0.090 |
Why?
|
| Daunorubicin | 2 | 2008 | 78 | 0.090 |
Why?
|
| Vomiting | 4 | 2014 | 195 | 0.090 |
Why?
|
| Electroencephalography | 1 | 1995 | 751 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2011 | 181 | 0.090 |
Why?
|
| Rituximab | 1 | 2010 | 119 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 2010 | 401 | 0.090 |
Why?
|
| Software | 2 | 2017 | 664 | 0.090 |
Why?
|
| Kidney Function Tests | 2 | 2007 | 114 | 0.080 |
Why?
|
| Motivation | 4 | 2012 | 296 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1653 | 0.080 |
Why?
|
| Publishing | 1 | 2010 | 90 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1225 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 106 | 0.080 |
Why?
|
| International Normalized Ratio | 1 | 2009 | 39 | 0.080 |
Why?
|
| Mucositis | 1 | 2009 | 18 | 0.080 |
Why?
|
| Podophyllotoxin | 3 | 1994 | 10 | 0.080 |
Why?
|
| Pain | 2 | 2022 | 399 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 922 | 0.080 |
Why?
|
| Blood Cell Count | 6 | 1999 | 79 | 0.080 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2008 | 2 | 0.080 |
Why?
|
| Forecasting | 2 | 2008 | 306 | 0.080 |
Why?
|
| RecQ Helicases | 1 | 2008 | 7 | 0.080 |
Why?
|
| Acute Disease | 4 | 2014 | 841 | 0.080 |
Why?
|
| Werner Syndrome | 1 | 2008 | 2 | 0.080 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 37 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2019 | 871 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2008 | 31 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 4 | 1998 | 565 | 0.080 |
Why?
|
| Exodeoxyribonucleases | 1 | 2008 | 17 | 0.080 |
Why?
|
| Developed Countries | 1 | 2008 | 25 | 0.080 |
Why?
|
| Health Care Sector | 1 | 2008 | 13 | 0.080 |
Why?
|
| Enterohepatic Circulation | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hep G2 Cells | 3 | 2013 | 48 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 552 | 0.080 |
Why?
|
| Personal Autonomy | 4 | 1998 | 116 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 573 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 73 | 0.080 |
Why?
|
| Injections, Subcutaneous | 3 | 2004 | 125 | 0.080 |
Why?
|
| Stereoisomerism | 3 | 2008 | 102 | 0.080 |
Why?
|
| Immunotoxins | 2 | 1998 | 14 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2008 | 73 | 0.070 |
Why?
|
| Economics, Medical | 1 | 2007 | 6 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 198 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2662 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2009 | 261 | 0.070 |
Why?
|
| Carmustine | 2 | 2000 | 70 | 0.070 |
Why?
|
| Everolimus | 1 | 2007 | 40 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 890 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2014 | 246 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2007 | 134 | 0.070 |
Why?
|
| Hypotension | 3 | 2004 | 71 | 0.070 |
Why?
|
| Insurance | 1 | 2007 | 12 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 842 | 0.070 |
Why?
|
| Age Factors | 4 | 2014 | 1872 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2021 | 293 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 181 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 157 | 0.070 |
Why?
|
| Base Sequence | 3 | 2008 | 2327 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2010 | 354 | 0.070 |
Why?
|
| Employment | 1 | 2007 | 53 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 306 | 0.070 |
Why?
|
| Observer Variation | 1 | 2008 | 610 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 313 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2003 | 334 | 0.070 |
Why?
|
| Medication Errors | 1 | 2007 | 39 | 0.070 |
Why?
|
| Serum Albumin | 3 | 1995 | 127 | 0.070 |
Why?
|
| Nogalamycin | 1 | 1986 | 2 | 0.070 |
Why?
|
| Tea | 1 | 2006 | 21 | 0.070 |
Why?
|
| Molecular Structure | 1 | 2007 | 290 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 154 | 0.070 |
Why?
|
| Thymidine | 1 | 1986 | 59 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2011 | 389 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 192 | 0.070 |
Why?
|
| Catechin | 1 | 2006 | 24 | 0.070 |
Why?
|
| Photosensitivity Disorders | 1 | 2006 | 16 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1863 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 413 | 0.070 |
Why?
|
| Keratosis | 1 | 2006 | 21 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 353 | 0.070 |
Why?
|
| Complementary Therapies | 1 | 2007 | 56 | 0.070 |
Why?
|
| Infusion Pumps | 5 | 1989 | 25 | 0.070 |
Why?
|
| Asthma | 1 | 2014 | 977 | 0.070 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2006 | 24 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 3027 | 0.070 |
Why?
|
| Drug Combinations | 3 | 2010 | 203 | 0.070 |
Why?
|
| Genes, ras | 1 | 2006 | 98 | 0.070 |
Why?
|
| Patients | 1 | 2007 | 102 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2013 | 9060 | 0.070 |
Why?
|
| Mice | 6 | 2016 | 11766 | 0.070 |
Why?
|
| Foot Dermatoses | 1 | 1985 | 3 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 740 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 1997 | 302 | 0.060 |
Why?
|
| Hand Dermatoses | 1 | 1985 | 9 | 0.060 |
Why?
|
| Neutrophils | 3 | 2002 | 308 | 0.060 |
Why?
|
| Adsorption | 1 | 2005 | 54 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2008 | 211 | 0.060 |
Why?
|
| Furans | 1 | 2005 | 16 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 127 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2005 | 65 | 0.060 |
Why?
|
| Filgrastim | 2 | 2003 | 57 | 0.060 |
Why?
|
| Phenylenediamines | 1 | 2004 | 7 | 0.060 |
Why?
|
| Thiophenes | 3 | 2000 | 43 | 0.060 |
Why?
|
| Meperidine | 1 | 2004 | 13 | 0.060 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 240 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2004 | 14 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2004 | 9 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 37 | 0.060 |
Why?
|
| Capsules | 1 | 2004 | 37 | 0.060 |
Why?
|
| Transaminases | 1 | 2004 | 33 | 0.060 |
Why?
|
| Quinolones | 1 | 2004 | 60 | 0.060 |
Why?
|
| In Vitro Techniques | 3 | 2015 | 996 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2008 | 739 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 69 | 0.060 |
Why?
|
| Coformycin | 3 | 1989 | 9 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2014 | 40 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 153 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2014 | 78 | 0.060 |
Why?
|
| Formaldehyde | 2 | 2014 | 52 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 397 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2004 | 59 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2010 | 78 | 0.060 |
Why?
|
| Greenhouse Effect | 1 | 2023 | 2 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2004 | 85 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2004 | 52 | 0.060 |
Why?
|
| Mouth Mucosa | 2 | 2014 | 68 | 0.060 |
Why?
|
| Idoxuridine | 2 | 1993 | 16 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2004 | 131 | 0.060 |
Why?
|
| Pelvis | 1 | 2003 | 96 | 0.060 |
Why?
|
| Alkaline Phosphatase | 4 | 2002 | 132 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2002 | 18 | 0.050 |
Why?
|
| Chromium | 1 | 2002 | 17 | 0.050 |
Why?
|
| Endostatins | 1 | 2002 | 6 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2005 | 172 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2022 | 17 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2020 | 3733 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 33 | 0.050 |
Why?
|
| CHO Cells | 1 | 2002 | 188 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 449 | 0.050 |
Why?
|
| Morphine | 1 | 2003 | 130 | 0.050 |
Why?
|
| Hydralazine | 1 | 2022 | 19 | 0.050 |
Why?
|
| Protein Kinase C-alpha | 1 | 2002 | 27 | 0.050 |
Why?
|
| Killer Cells, Natural | 2 | 2002 | 276 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2022 | 46 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Population | 1 | 2002 | 35 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2002 | 691 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2022 | 60 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 1800 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.050 |
Why?
|
| Anorexia | 1 | 2001 | 30 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2002 | 92 | 0.050 |
Why?
|
| Cricetinae | 1 | 2002 | 558 | 0.050 |
Why?
|
| Point Mutation | 1 | 2002 | 245 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 237 | 0.050 |
Why?
|
| Carbon Radioisotopes | 1 | 2001 | 35 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2001 | 29 | 0.050 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.050 |
Why?
|
| Anthropometry | 1 | 2001 | 75 | 0.050 |
Why?
|
| Data Collection | 2 | 2000 | 375 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2001 | 83 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2001 | 153 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2001 | 92 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2367 | 0.050 |
Why?
|
| Neurites | 1 | 2020 | 36 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 866 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2000 | 75 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1072 | 0.040 |
Why?
|
| Carcinoma | 1 | 2004 | 443 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 20 | 0.040 |
Why?
|
| Lactones | 1 | 2000 | 27 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 270 | 0.040 |
Why?
|
| Macrolides | 1 | 2000 | 31 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 249 | 0.040 |
Why?
|
| Interferons | 4 | 1990 | 126 | 0.040 |
Why?
|
| Glutathione | 2 | 2000 | 108 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 57 | 0.040 |
Why?
|
| Colonic Polyps | 1 | 2000 | 132 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 359 | 0.040 |
Why?
|
| Gene Expression | 2 | 2014 | 1310 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2004 | 899 | 0.040 |
Why?
|
| Hypoxia | 1 | 2004 | 653 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Codeine | 1 | 2019 | 12 | 0.040 |
Why?
|
| Myosin Type II | 1 | 2019 | 50 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2019 | 91 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2020 | 99 | 0.040 |
Why?
|
| Feces | 1 | 2001 | 331 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 129 | 0.040 |
Why?
|
| Hospitalization | 2 | 2019 | 877 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1998 | 15 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2018 | 49 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 1996 | 78 | 0.040 |
Why?
|
| Ribonucleosides | 2 | 1989 | 25 | 0.040 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1998 | 15 | 0.040 |
Why?
|
| Organic Anion Transporters | 2 | 2009 | 26 | 0.040 |
Why?
|
| Crigler-Najjar Syndrome | 1 | 1998 | 3 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 1998 | 29 | 0.040 |
Why?
|
| Zidovudine | 1 | 1998 | 16 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 5 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 1999 | 125 | 0.040 |
Why?
|
| Nitrophenols | 1 | 1998 | 11 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 69 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1998 | 62 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 308 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 345 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 482 | 0.040 |
Why?
|
| Exons | 2 | 2011 | 451 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
| Causality | 1 | 1998 | 80 | 0.040 |
Why?
|
| Infant | 2 | 2020 | 3161 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2019 | 95 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2002 | 657 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 1997 | 42 | 0.040 |
Why?
|
| Consent Forms | 2 | 1995 | 11 | 0.040 |
Why?
|
| Vinca Alkaloids | 1 | 1997 | 3 | 0.040 |
Why?
|
| Cosyntropin | 1 | 1996 | 5 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2015 | 155 | 0.040 |
Why?
|
| Isotretinoin | 1 | 1997 | 23 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 251 | 0.040 |
Why?
|
| Thiotepa | 2 | 2004 | 32 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 470 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 460 | 0.030 |
Why?
|
| Aldosterone | 1 | 1996 | 56 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1996 | 131 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 215 | 0.030 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 13 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 329 | 0.030 |
Why?
|
| Morphine Derivatives | 2 | 2008 | 8 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 387 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 374 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2017 | 187 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3448 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 505 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2009 | 332 | 0.030 |
Why?
|
| Keratoacanthoma | 1 | 1996 | 4 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 1996 | 68 | 0.030 |
Why?
|
| Vitamin D | 1 | 2018 | 269 | 0.030 |
Why?
|
| Biological Transport | 2 | 2002 | 401 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 502 | 0.030 |
Why?
|
| Digestive System Diseases | 1 | 1996 | 18 | 0.030 |
Why?
|
| Life Tables | 1 | 1995 | 48 | 0.030 |
Why?
|
| Quality Control | 1 | 2016 | 117 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 106 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 294 | 0.030 |
Why?
|
| Bleomycin | 2 | 1993 | 102 | 0.030 |
Why?
|
| Microsomes | 1 | 2015 | 35 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 169 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2014 | 1654 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 458 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 1988 | 451 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 360 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1237 | 0.030 |
Why?
|
| Lung | 2 | 2014 | 1262 | 0.030 |
Why?
|
| Bias | 2 | 1995 | 134 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2011 | 1076 | 0.030 |
Why?
|
| Chromatography, Liquid | 2 | 2010 | 106 | 0.030 |
Why?
|
| Blast Crisis | 1 | 1995 | 37 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 1996 | 142 | 0.030 |
Why?
|
| Linear Models | 1 | 1996 | 421 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2008 | 794 | 0.030 |
Why?
|
| Coma | 1 | 1995 | 47 | 0.030 |
Why?
|
| Body Mass Index | 1 | 1998 | 773 | 0.030 |
Why?
|
| Peroxisome-Targeting Signal 1 Receptor | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 80 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2014 | 36 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 308 | 0.030 |
Why?
|
| Budesonide | 1 | 2014 | 46 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 477 | 0.030 |
Why?
|
| Antineoplastic Protocols | 1 | 2014 | 9 | 0.030 |
Why?
|
| Blindness | 1 | 1994 | 39 | 0.030 |
Why?
|
| Lymphocytes | 3 | 2004 | 471 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 18 | 0.030 |
Why?
|
| Prostate | 1 | 2018 | 393 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 163 | 0.030 |
Why?
|
| Cell Line | 2 | 2010 | 2496 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 387 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2007 | 392 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 144 | 0.030 |
Why?
|
| Body Height | 1 | 2014 | 100 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 22 | 0.030 |
Why?
|
| Arylsulfotransferase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2013 | 16 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2017 | 350 | 0.030 |
Why?
|
| Sulfotransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 852 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1994 | 150 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 683 | 0.030 |
Why?
|
| Dacarbazine | 1 | 1994 | 102 | 0.030 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1993 | 82 | 0.030 |
Why?
|
| Anthracenes | 1 | 1993 | 15 | 0.030 |
Why?
|
| Drug Stability | 1 | 2013 | 49 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 177 | 0.030 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2013 | 50 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 64 | 0.030 |
Why?
|
| Ethical Review | 1 | 1992 | 8 | 0.030 |
Why?
|
| Cattle | 1 | 2013 | 376 | 0.030 |
Why?
|
| Blood | 1 | 1993 | 69 | 0.030 |
Why?
|
| Receptor, EphA5 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 45 | 0.030 |
Why?
|
| Blood Transfusion | 2 | 1991 | 169 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 148 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 856 | 0.030 |
Why?
|
| Dogs | 1 | 2013 | 704 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 112 | 0.030 |
Why?
|
| Sepsis | 1 | 1996 | 321 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 130 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1992 | 54 | 0.030 |
Why?
|
| Insurance Benefits | 1 | 2012 | 8 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 106 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 727 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1991 | 48 | 0.020 |
Why?
|
| Monocytes | 3 | 1994 | 218 | 0.020 |
Why?
|
| Intellectual Property | 1 | 2011 | 3 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 502 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 684 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 48 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 529 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2013 | 200 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.020 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1991 | 17 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 23 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 62 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2002 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 33 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1992 | 266 | 0.020 |
Why?
|
| Allelic Imbalance | 1 | 2011 | 22 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 94 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2012 | 253 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1993 | 265 | 0.020 |
Why?
|
| Public Sector | 1 | 2010 | 12 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 212 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2013 | 466 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 160 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2010 | 13 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 52 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2002 | 42 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 507 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1991 | 171 | 0.020 |
Why?
|
| Hymecromone | 1 | 2010 | 4 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 104 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2011 | 646 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2010 | 11 | 0.020 |
Why?
|
| Imipramine | 1 | 2010 | 16 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 805 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 146 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2010 | 133 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2010 | 50 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 342 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 446 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1488 | 0.020 |
Why?
|
| Aging | 1 | 1994 | 718 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 184 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 179 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 183 | 0.020 |
Why?
|
| Leukemia L1210 | 1 | 1988 | 12 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3220 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2009 | 66 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2010 | 200 | 0.020 |
Why?
|
| Melphalan | 1 | 1989 | 98 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 234 | 0.020 |
Why?
|
| Werner Syndrome Helicase | 1 | 2008 | 2 | 0.020 |
Why?
|
| Osteolysis | 1 | 1988 | 14 | 0.020 |
Why?
|
| Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
| Thiones | 2 | 2000 | 10 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2014 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 97 | 0.020 |
Why?
|
| Rats, Inbred Dahl | 1 | 2008 | 8 | 0.020 |
Why?
|
| Complement C1q | 1 | 2008 | 11 | 0.020 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1989 | 283 | 0.020 |
Why?
|
| Recurrence | 2 | 2008 | 1144 | 0.020 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2008 | 33 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1597 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2007 | 12 | 0.020 |
Why?
|
| Karyotyping | 1 | 1987 | 253 | 0.020 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 1998 | 28 | 0.020 |
Why?
|
| Xenobiotics | 1 | 2007 | 7 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 264 | 0.020 |
Why?
|
| Informatics | 1 | 2007 | 5 | 0.020 |
Why?
|
| Cytarabine | 1 | 2008 | 219 | 0.020 |
Why?
|
| Herb-Drug Interactions | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 84 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 103 | 0.020 |
Why?
|
| Aerosols | 1 | 2007 | 45 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 73 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 1987 | 47 | 0.020 |
Why?
|
| Hydroxytestosterones | 1 | 2006 | 1 | 0.020 |
Why?
|
| Plant Preparations | 1 | 2007 | 21 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 227 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2006 | 10 | 0.020 |
Why?
|
| Menogaril | 1 | 1986 | 3 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 275 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 1986 | 51 | 0.020 |
Why?
|
| Thymine | 1 | 1986 | 17 | 0.020 |
Why?
|
| Digestive System | 1 | 1986 | 42 | 0.020 |
Why?
|
| Hyponatremia | 1 | 1986 | 28 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 190 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 698 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1989 | 296 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 426 | 0.020 |
Why?
|
| Empirical Research | 2 | 1997 | 19 | 0.020 |
Why?
|
| Vitamins | 1 | 2007 | 83 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2007 | 125 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 983 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 143 | 0.020 |
Why?
|
| Mephenytoin | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2004 | 6 | 0.020 |
Why?
|
| Fluvoxamine | 1 | 2004 | 7 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2007 | 269 | 0.020 |
Why?
|
| Receptors, Endothelin | 1 | 2004 | 12 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2005 | 205 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2008 | 730 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 306 | 0.010 |
Why?
|
| Vincristine | 2 | 1997 | 112 | 0.010 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2003 | 16 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 72 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2007 | 681 | 0.010 |
Why?
|
| Contrast Media | 1 | 2008 | 1092 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2008 | 779 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 415 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 657 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2004 | 344 | 0.010 |
Why?
|
| Propofol | 1 | 2002 | 92 | 0.010 |
Why?
|
| Global Health | 1 | 2002 | 188 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 205 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2000 | 207 | 0.010 |
Why?
|
| Rectum | 1 | 2000 | 148 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1998 | 44 | 0.010 |
Why?
|
| Shivering | 1 | 1998 | 4 | 0.010 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1998 | 3 | 0.010 |
Why?
|
| Methotrexate | 2 | 1989 | 250 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 1998 | 9 | 0.010 |
Why?
|
| Platelet Count | 2 | 1989 | 93 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 200 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 269 | 0.010 |
Why?
|
| Persons | 1 | 1997 | 6 | 0.010 |
Why?
|
| Control Groups | 1 | 1997 | 15 | 0.010 |
Why?
|
| Federal Government | 1 | 1997 | 29 | 0.010 |
Why?
|
| Paternalism | 1 | 1997 | 24 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 146 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1997 | 34 | 0.010 |
Why?
|
| Patient Advocacy | 1 | 1997 | 53 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 81 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 809 | 0.010 |
Why?
|
| Ligands | 1 | 1998 | 445 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 1997 | 83 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1998 | 576 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1997 | 193 | 0.010 |
Why?
|
| Brain | 1 | 1986 | 2285 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 88 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 1995 | 40 | 0.010 |
Why?
|
| Menopause | 1 | 1995 | 76 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 1996 | 114 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
| Cultural Diversity | 1 | 1995 | 57 | 0.010 |
Why?
|
| Educational Status | 1 | 1995 | 195 | 0.010 |
Why?
|
| Truth Disclosure | 1 | 1995 | 93 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 66 | 0.010 |
Why?
|
| Benzofurans | 1 | 1994 | 9 | 0.010 |
Why?
|
| Trust | 1 | 1995 | 98 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 1992 | 7 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 1992 | 29 | 0.010 |
Why?
|
| Hemoglobin A | 1 | 1992 | 8 | 0.010 |
Why?
|
| 2-Chloroadenosine | 1 | 1992 | 5 | 0.010 |
Why?
|
| Deoxyadenosines | 1 | 1992 | 23 | 0.010 |
Why?
|
| Platinum | 1 | 1992 | 63 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1993 | 170 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1993 | 161 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1993 | 496 | 0.010 |
Why?
|
| Absorption | 1 | 1989 | 25 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1988 | 34 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1988 | 23 | 0.000 |
Why?
|
| Chromatography, Gas | 1 | 1988 | 28 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1987 | 153 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1986 | 16 | 0.000 |
Why?
|
| Erythrocyte Transfusion | 1 | 1986 | 72 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1988 | 1597 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 1224 | 0.000 |
Why?
|